<div id="readability-page-1"><p>Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Get Free Report) saw unusually large options trading on Wednesday. Stock investors acquired 25,745 call options on the company. This is an increase of 295% compared to the average volume of 6,521 call options.</p><div><p><span></span><span>Get <strong>Reviva Pharmaceuticals</strong> alerts:</span></p></div><h2>Analyst Upgrades and Downgrades</h2><p>RVPH has been the topic of a number of research reports. D. Boral Capital  reissued a &#34;buy&#34; rating and issued a $2.00 price objective on shares of Reviva Pharmaceuticals in a report on Tuesday. Benchmark dropped their price target on shares of Reviva Pharmaceuticals from $14.00 to $7.00 and set a &#34;speculative buy&#34; rating on the stock in a research note on Monday, September 15th. HC Wainwright lowered their target price on shares of Reviva Pharmaceuticals from $11.00 to $4.00 and set a &#34;buy&#34; rating on the stock in a report on Monday, October 27th. Weiss Ratings  restated a &#34;sell (e+)&#34; rating on shares of Reviva Pharmaceuticals in a research report on Wednesday, October 8th. Finally, Wall Street Zen upgraded Reviva Pharmaceuticals to a &#34;sell&#34; rating in a research note on Saturday, October 4th. One investment analyst  has rated the stock with a Strong Buy rating, seven have given a Buy rating and one  has issued  a Sell rating to the company's stock. According to data from MarketBeat, the stock  has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $3.86.</p><p><b>Get Our Latest Analysis on RVPH</b></p><h2>Reviva Pharmaceuticals Trading Down 45.5%</h2><p>NASDAQ RVPH opened at $0.32 on Wednesday. The stock has a 50-day moving average of $0.57 and a 200-day moving average of $0.52. The firm has a market cap of $36.97 million, a PE ratio of -0.70 and a beta of -0.02. Reviva Pharmaceuticals has a 1-year low of $0.25 and a 1-year high of $2.17. </p><p>Reviva Pharmaceuticals (NASDAQ:RVPH - Get Free Report) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.05.  As a group, equities research analysts forecast that  Reviva Pharmaceuticals will post -0.97 earnings per share for the current fiscal year. </p><h2>Institutional Trading of Reviva Pharmaceuticals</h2><p>Several hedge funds and other institutional investors have recently made changes to their positions in RVPH. Armistice Capital LLC bought a new position in  Reviva Pharmaceuticals during the second quarter valued at approximately $1,026,000.  683 Capital Management LLC purchased a new stake in shares of  Reviva Pharmaceuticals in the 2nd quarter worth $381,000.  Persistent Asset Partners Ltd increased its position in  Reviva Pharmaceuticals by 300.0% in the second quarter. Persistent Asset Partners Ltd now owns 641,174 shares of the company's stock worth $244,000 after buying an additional 480,864 shares in the last quarter.  Millennium Management LLC raised its stake in  Reviva Pharmaceuticals by 15.0% during the 3rd quarter. Millennium Management LLC now owns 1,711,221 shares of the company's stock worth $631,000 after acquiring an additional 223,178 shares during the period.  Finally, Lido Advisors LLC bought a new stake in shares of  Reviva Pharmaceuticals during the 3rd quarter valued at $37,000. Hedge funds and other institutional investors own  63.18% of the company's stock. </p><h2>Reviva Pharmaceuticals Company Profile</h2> (Get Free Report)<p>Reviva Pharmaceuticals, Inc <span>NASDAQ: RVPH<span></span></span> is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.  </p><p>The company's core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Reviva Pharmaceuticals</li><li>The boring AI play that could pay up to $4,290 monthly</li><li>ALERT: Drop these 5 stocks before January 2026!</li><li>Trump’s “real estate deal for America” explained</li><li>A month before the crash</li><li>Put $1,000 into this stock by Jan 1 [Not NVDA]</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Reviva Pharmaceuticals Right Now?</h2><p>Before you consider Reviva Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Reviva Pharmaceuticals wasn't on the list.</p><p>While Reviva Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

RVPH

<p>Reviva Pharmaceuticals (NASDAQ:RVPH) experienced a 295% increase in call options trading, with 25,745 options acquired, compared to the average of 6,521. Analysts have mixed ratings, with a consensus of "Moderate Buy" and a price target of $3.86. The stock opened at $0.32, down 45.5%, with a market cap of $36.97 million. Institutional investors hold 63.18% of shares.</p>

Investors Purchase Large Volume of Call Options on Reviva Pharmaceuticals (NASDAQ:RVPH)